CCA subtypes exhibit high tumour cell heterogeneity, as well as specific genetic and epigenetic alterations, including frequent KRAS, TP53 and IDH1/2 mutation and FGFR2 gene fusions with enhanced tumourigenic activity (Kendall et al, 2019). The gene discussed is FGFR2; the disease is cholangiocarcinoma.